ANA Therapeutics $5mn seed round for COVID-19 treatment

By William Smith
ANA Therapeutics is a Silicon Valley, California-based biotech company developing a coronavirus vaccine...

ANA Therapeutics is a Silicon Valley, California-based biotech company developing a coronavirus vaccine. 

Founded earlier this year, the company has announced that the US Food and Drug Administration (FDA) has cleared its investigation into using niclosamide capsules as a potential COVID-19 treatment, allowing for human trials.

The company said it would perform the trial with 400 COVID-19 afflicted patients at 10 centres across the US. Specifically, these will be places experiencing a current surge such as Florida and Texas - with the aim being to entol the first patient in August.

The trial will assess niclosamide’s safety and its potential to alleviate symptoms. Niclosamide is a pre-existing drug chiefly used to treat tapeworm infections, but pre-clinical research conducted by the company has shown it to stop coronavirus from replicating.

The company yesterday announced a seed round raising $5mn from 11 investors, including the organisations SV Tech Ventures, SV Angel, SOSV, Refactor Capital and On Air Investments.

In a press release, ANA Co-Founder and CEO Akash Bakshi said: “Safe and effective antiviral therapies are critically needed to treat COVID-19 now and treatments will continue to be necessary even if a vaccine is developed. This will be the first U.S.- based clinical trial to determine the efficacy of niclosamide in COVID-19. Anticipating that niclosamide may prove to be effective against COVID-19, we are already laying plans to make the drug accessible to everyone.”

The company said that if proven to work, niclosamide had other benefits including being well tolerated and low-cost.

“As a start-up and unlike large life science companies, ANA Therapeutics has already moved at lightning speed to get niclosamide into clinical trials,” said Sam Altman, former president of Y Combinator and now the CEO of OpenAI. “I’m thrilled to invest in the team’s critically important mission to develop a safe, effective, and widely available treatment for COVID-19.”


Featured Articles

Honeywell comments on post-pandemic air quality challenges

Honeywell’s Sarah James calls for air sensors to ensure good air quality & Stefano D’Agostino explores how technology can help improve indoor air quality

Oracle's generative AI prioritises patient healthcare

Oracle's vision for better healthcare focuses on improving medical professionals quality time with patients, with Oracle Clinical Digital Assistant

2San's new app provides vital diagnostic product insights

2San’s leap forward in self diagnostics will bring ‘Better Care, Better Life’ to all, in a new step for 2San’s post-COVID-19 healthcare technology

Cylera’s Richard Staynings on healthcare cybersecurity

Technology & AI

Amazon Prime & One Medical to revolutionise healthcare

Digital Healthcare

Creating robust pharma supply chains with delivery devices

Medical Devices & Pharma